28.5 C
Vientiane
Friday, September 5, 2025
spot_img
Home Blog Page 323

Norgine welcomes PBS listing in Australia of IFINWIL® (eflornithine) for patients with high-risk neuroblastoma (HRNB)

This news is for Australian Media only

  • Eflornithine is now reimbursed by the government under Australia’s Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing of eflornithine for post-maintenance treatment to prevent relapse in patients with high-risk neuroblastoma (HRNB) who are in remission after receiving multiagent, multimodality therapy.1
  • Approximately 50 children in Australia are diagnosed with neuroblastoma each year, with nearly half classified as having high-risk neuroblastoma (HRNB). 3 These children are, on average, just 2 years old, and the average survival rate for those with HRNB is 50%.2

SYDNEY, Aug. 1, 2025 /PRNewswire/ — Norgine, announced today the inclusion of IFINWIL® (eflornithine) on Australia’s Pharmaceutical Benefits Scheme (PBS). This listing comes just 3 months after receiving registration by the Therapeutic Goods Administration (TGA) and represents a pivotal step in improving access to essential treatments for patients with high-risk neuroblastoma (HRNB) who are in remission after receiving multiagent, multimodality therapy.

 

Lucy Jones, CEO Neuroblastoma Australia, welcomed the news: “On behalf of all families of children impacted by neuroblastoma, we welcome the PBS listing of IFINWIL®. We urgently need treatments for children diagnosed with neuroblastoma and this listing ensures every child in Australia has equal access to a new therapy for this aggressive and complex cancer. Providing options to new treatments is critical in ensuring every child diagnosed has the best chance of survival.”

“We thank the Federal Government for their support in ensuring early access to this treatment prior to TGA approval and PBS listing, which enabled children with high-risk disease to access the treatment within a time critical treatment window. We look forward to continued support for children with aggressive cancers.”

HRNB is a rare but aggressive form of cancer, predominantly affecting children and most commonly presenting in the first 5 years of life.2 Each year in Australia, approximately 50 children are diagnosed with neuroblastoma, with about half of these cases being classified as high-risk neuroblastoma.3 Neuroblastoma originates in the body’s nerve cells (neuroblasts) and typically presents as a primary tumour in the adrenal glands.4 It is considered an aggressive tumour because it often spreads to other parts of the body (metastasises). In most cases, it has spread by the time it is diagnosed.4

Eflornithine (DFMO) is a new treatment for high-risk neuroblastoma, an aggressive cancer seen mainly in infants and young children, said Dr. Toby Trahair, Paediatric Oncologist at the Sydney Children’s HospitalHaving access to eflornithine (DFMO) provides clinicians with a much-needed therapeutic option. It’s great to see that this new oral medication will be available to all Australian families through the PBS.”

The PBS listing of eflornithine is a landmark moment for families affected by high-risk neuroblastoma in Australia,” said Gus Rudolph, General Manager, Australia at Norgine. “This decision reflects the growing recognition of the urgent need for new treatment options in paediatric oncology. High-risk neuroblastoma has limited therapeutic pathways and eflornithine offers a new approach. We are grateful to the Australian Government for providing clinicians with access to this innovative therapy and remain committed to advancing solutions in areas of high unmet medical need.”

Please refer to the IFINWIL® Consumer Medicines Information (CMI) for full safety information on risks, side effects and precautions including the risk of low red blood cells (anaemia), low neutrophils (blood cells that fight infection), low platelets (clotting cells), increase in liver enzymes, and hearing loss or problems balancing.

Parents should speak to their doctor for guidance on the best treatment approach for their child.

Additional Information about IFINWIL® (eflornithine)

PBS Information. Authority required. Section 100 Highly Specialised Drugs Program. Restrictions Apply. Please refer to the PBS schedule for more details.

Indication: For the treatment of adults and paediatric patients with high-risk neuroblastoma (HRNB) who have responded to prior multiagent, multimodality therapy.

Contraindications: Hypersensitivity to eflornithine or to any of the excipients.

Special Warnings and Precautions: myelosuppression, hepatotoxicity, hearing loss / hypoacusis, use in renal impairment, elderly, paediatric patients.

Interactions: No in-vivo drug interaction studies have been performed with other medicinal products.

▼This medicine is subject to additional monitoring due to approval of an extension of indications. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.

Dr. Toby Trahair has served on advisory boards and participated in symposia sponsored by Norgine for which compensation was received. In relation to this Norgine media announcement, no compensation was provided to Dr. Trahair, and the opinions expressed are his own. Dr. Trahair has been briefed by Norgine on the approved use of this product.

NOTES TO EDITORS

About IFINWIL®
IFINWIL® has been investigated for use as a post maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients after first line multiagent, multimodality therapy.5 IFINWIL® is a therapy that blocks an enzyme called ornithine decarboxylase (ODC) responsible for producing polyamines, which are important to tumour growth and development.6

For more information on IFINWIL®, find the Public Summary Document here: Pharmaceutical Benefits Scheme (PBS) | Eflornithine; Tablet 192 mg (as hydrochloride); Ifinwil®  or speak to your healthcare practitioner.

High-Risk Neuroblastoma (HRNB) Treatment Background
Children diagnosed with HRNB undergo an intense treatment regimen that still leaves them vulnerable to relapse and death.7 Although there have been some improvements in survival, the prognosis for children with high risk neuroblastoma is still poor with around 80% of high risk relapses occuring within 2 years from diagnosis, and long-term survival remains low, with only about 15% surviving more than 5 years post-relapse.7,8,9 Avoiding relapse is key to long-term survival, and until now, there have been no approved therapies for the post maintenance treatment period in major markets outside of the United States.10

About Norgine
Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people’s lives drives everything we do, and our European experience, fully integrated infrastructure and exceptional partnership approach enable us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped more than 25 million patients around the world in 2022 and generated €530 million in net product sales, a growth of nearly 5% over 2021.

Norgine has a direct presence in 16 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

References

1.  Australian Public Summary Document: Pharmaceutical Benefits Scheme (PBS) | Eflornithine; Tablet 192 mg (as hydrochloride); Ifinwil® . Accessed July 2025
2.  https://www.neuroblastoma.org.au/about-key-statistics. Accessed July 2025
3.  ANZCHOG-Position-Statement-Eflornithine-DFMO-use-for-patients-with-high-risk-neuroblastoma-in-Australia-and-New-Zealand-v2.0-23.08.2024.pdf. Accessed July 2025
4.  https://rarediseases.info.nih.gov/diseases/7185/neuroblastoma. Accessed July 2025
5.  Clinical Trial NCT02395666; Preventative trial of difluoromethylornithine (DFMO) in high risk patients with neuroblastoma that is in remission. Available from: Study Details | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | ClinicalTrials.gov. Accessed July 2025
6.  Meyskens FL Jr, Gerner EW. Development of Difluoromethylornithine (DFMO) as a Chemoprevention Agent. Clin Cancer Res. 1999 May;5(5):945-51
7.  Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048-57.
8.  Desai A, et al. Outcomes Following GD2-Directed Post consolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children’s Oncology Group. J Clin Oncol. 2022 Jul; JCO2102478.
9.  London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017;123:4914-23.
10.  FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA. Accessed July 2025

 

Job Number: AU-ONC-IFW-2500008
Date of preparation: July 2025

Norgine welcomes PBS listing in Australia of IFINWIL® (eflornithine) for patients with high-risk neuroblastoma (HRNB)

This news is for Australian Media only

  • Eflornithine is now reimbursed by the government under Australia’s Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing of eflornithine for post-maintenance treatment to prevent relapse in patients with high-risk neuroblastoma (HRNB) who are in remission after receiving multiagent, multimodality therapy.1
  • Approximately 50 children in Australia are diagnosed with neuroblastoma each year, with nearly half classified as having high-risk neuroblastoma (HRNB). 3 These children are, on average, just 2 years old, and the average survival rate for those with HRNB is 50%.2

SYDNEY, Aug. 1, 2025 /PRNewswire/ — Norgine, announced today the inclusion of IFINWIL® (eflornithine) on Australia’s Pharmaceutical Benefits Scheme (PBS). This listing comes just 3 months after receiving registration by the Therapeutic Goods Administration (TGA) and represents a pivotal step in improving access to essential treatments for patients with high-risk neuroblastoma (HRNB) who are in remission after receiving multiagent, multimodality therapy.

 

Lucy Jones, CEO Neuroblastoma Australia, welcomed the news: “On behalf of all families of children impacted by neuroblastoma, we welcome the PBS listing of IFINWIL®. We urgently need treatments for children diagnosed with neuroblastoma and this listing ensures every child in Australia has equal access to a new therapy for this aggressive and complex cancer. Providing options to new treatments is critical in ensuring every child diagnosed has the best chance of survival.”

“We thank the Federal Government for their support in ensuring early access to this treatment prior to TGA approval and PBS listing, which enabled children with high-risk disease to access the treatment within a time critical treatment window. We look forward to continued support for children with aggressive cancers.”

HRNB is a rare but aggressive form of cancer, predominantly affecting children and most commonly presenting in the first 5 years of life.2 Each year in Australia, approximately 50 children are diagnosed with neuroblastoma, with about half of these cases being classified as high-risk neuroblastoma.3 Neuroblastoma originates in the body’s nerve cells (neuroblasts) and typically presents as a primary tumour in the adrenal glands.4 It is considered an aggressive tumour because it often spreads to other parts of the body (metastasises). In most cases, it has spread by the time it is diagnosed.4

Eflornithine (DFMO) is a new treatment for high-risk neuroblastoma, an aggressive cancer seen mainly in infants and young children, said Dr. Toby Trahair, Paediatric Oncologist at the Sydney Children’s HospitalHaving access to eflornithine (DFMO) provides clinicians with a much-needed therapeutic option. It’s great to see that this new oral medication will be available to all Australian families through the PBS.”

The PBS listing of eflornithine is a landmark moment for families affected by high-risk neuroblastoma in Australia,” said Gus Rudolph, General Manager, Australia at Norgine. “This decision reflects the growing recognition of the urgent need for new treatment options in paediatric oncology. High-risk neuroblastoma has limited therapeutic pathways and eflornithine offers a new approach. We are grateful to the Australian Government for providing clinicians with access to this innovative therapy and remain committed to advancing solutions in areas of high unmet medical need.”

Please refer to the IFINWIL® Consumer Medicines Information (CMI) for full safety information on risks, side effects and precautions including the risk of low red blood cells (anaemia), low neutrophils (blood cells that fight infection), low platelets (clotting cells), increase in liver enzymes, and hearing loss or problems balancing.

Parents should speak to their doctor for guidance on the best treatment approach for their child.

Additional Information about IFINWIL® (eflornithine)

PBS Information. Authority required. Section 100 Highly Specialised Drugs Program. Restrictions Apply. Please refer to the PBS schedule for more details.

Indication: For the treatment of adults and paediatric patients with high-risk neuroblastoma (HRNB) who have responded to prior multiagent, multimodality therapy.

Contraindications: Hypersensitivity to eflornithine or to any of the excipients.

Special Warnings and Precautions: myelosuppression, hepatotoxicity, hearing loss / hypoacusis, use in renal impairment, elderly, paediatric patients.

Interactions: No in-vivo drug interaction studies have been performed with other medicinal products.

▼This medicine is subject to additional monitoring due to approval of an extension of indications. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.

Dr. Toby Trahair has served on advisory boards and participated in symposia sponsored by Norgine for which compensation was received. In relation to this Norgine media announcement, no compensation was provided to Dr. Trahair, and the opinions expressed are his own. Dr. Trahair has been briefed by Norgine on the approved use of this product.

NOTES TO EDITORS

About IFINWIL®
IFINWIL® has been investigated for use as a post maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients after first line multiagent, multimodality therapy.5 IFINWIL® is a therapy that blocks an enzyme called ornithine decarboxylase (ODC) responsible for producing polyamines, which are important to tumour growth and development.6

For more information on IFINWIL®, find the Public Summary Document here: Pharmaceutical Benefits Scheme (PBS) | Eflornithine; Tablet 192 mg (as hydrochloride); Ifinwil®  or speak to your healthcare practitioner.

High-Risk Neuroblastoma (HRNB) Treatment Background
Children diagnosed with HRNB undergo an intense treatment regimen that still leaves them vulnerable to relapse and death.7 Although there have been some improvements in survival, the prognosis for children with high risk neuroblastoma is still poor with around 80% of high risk relapses occuring within 2 years from diagnosis, and long-term survival remains low, with only about 15% surviving more than 5 years post-relapse.7,8,9 Avoiding relapse is key to long-term survival, and until now, there have been no approved therapies for the post maintenance treatment period in major markets outside of the United States.10

About Norgine
Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people’s lives drives everything we do, and our European experience, fully integrated infrastructure and exceptional partnership approach enable us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped more than 25 million patients around the world in 2022 and generated €530 million in net product sales, a growth of nearly 5% over 2021.

Norgine has a direct presence in 16 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

References

1.  Australian Public Summary Document: Pharmaceutical Benefits Scheme (PBS) | Eflornithine; Tablet 192 mg (as hydrochloride); Ifinwil® . Accessed July 2025
2.  https://www.neuroblastoma.org.au/about-key-statistics. Accessed July 2025
3.  ANZCHOG-Position-Statement-Eflornithine-DFMO-use-for-patients-with-high-risk-neuroblastoma-in-Australia-and-New-Zealand-v2.0-23.08.2024.pdf. Accessed July 2025
4.  https://rarediseases.info.nih.gov/diseases/7185/neuroblastoma. Accessed July 2025
5.  Clinical Trial NCT02395666; Preventative trial of difluoromethylornithine (DFMO) in high risk patients with neuroblastoma that is in remission. Available from: Study Details | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | ClinicalTrials.gov. Accessed July 2025
6.  Meyskens FL Jr, Gerner EW. Development of Difluoromethylornithine (DFMO) as a Chemoprevention Agent. Clin Cancer Res. 1999 May;5(5):945-51
7.  Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048-57.
8.  Desai A, et al. Outcomes Following GD2-Directed Post consolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children’s Oncology Group. J Clin Oncol. 2022 Jul; JCO2102478.
9.  London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017;123:4914-23.
10.  FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA. Accessed July 2025

 

Job Number: AU-ONC-IFW-2500008
Date of preparation: July 2025

Shell completes sale of interest in Colonial Enterprises Inc. to Brookfield subsidiary

HOUSTON, Aug. 1, 2025 /PRNewswire/ — Shell Midstream Operating LLC (SMUS), a subsidiary of Shell plc (“Shell”), has completed the previously announced sale of its 16.125% interest in Colonial Enterprises, Inc. (“Colonial”) to Colossus AcquireCo LLC, a wholly owned subsidiary of Brookfield Infrastructure Partners L.P. and its institutional partners (collectively, “Brookfield”).

The divestment reflects Shell’s focus on performance, discipline and simplification and enables the company to concentrate on areas where it has scale and competitive advantage.

Notes to editors 

  • Together with Shell, the co-owners of Colonial Enterprises, Inc., have sold 100% of their Colonial shares to Brookfield. Colonial was previously divided among five partners: Shell Midstream Operating LLC (16.125%), Koch Capital Investments Company, LLC (28.088%); KKR-Keats Pipeline Investors, L.P. (23.443%); La Caisse (16.549%); and IFM Investors (IFM) (15.795%).
  • The sale values Shell’s share of Colonial at $1.45 billion, inclusive of approximately $500 million in non-recourse debt and excluding customary closing adjustments.
  • Colonial operates as an independent company and fully owns Colonial Pipeline Company (CPC), a non-operated venture, as well as Colonial Marketing Company. CPC provides oil products transportation services from the US Gulf Coast to the US Atlantic Seaboard.
  • Shell Midstream Operating LLC is an indirect, wholly owned subsidiary of Shell Pipeline Company LP, and the largest pipeline operator in the Gulf of America. It transports 1.5 billion barrels of crude oil, refined products, chemicals and NGLs annually through its vast network of pipelines and tank farms across 12 states and the Gulf of America.
  • The U.S. is a key market for Shell, where it has interests in 50 states and employs more than 11,000 people who work to provide a secure supply of energy today, while tackling the energy challenges of the future. Shell’s U.S. portfolio of operated companies and interests consists of oil, natural gas, petrochemicals, lubricants and refined fuel products along with renewables such as wind, solar, and mobility segments like electric vehicle charging.

Cautionary Note

The companies in which Shell plc directly and indirectly owns investments are separate legal entities. In this press release, “Shell”, “Shell Group” and “Group” are sometimes used for convenience to reference Shell plc and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Shell plc and its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. ”Subsidiaries”, “Shell subsidiaries” and “Shell companies” as used in this press release refer to entities over which Shell plc either directly or indirectly has control. The terms “joint venture”, “joint operations”, “joint arrangements”, and “associates” may also be used to refer to a commercial arrangement in which Shell has a direct or indirect ownership interest with one or more parties.  The term “Shell interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.

Forward-Looking statements

This press release contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition, results of operations and businesses of Shell. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Shell to market risks and statements expressing management’s expectations, beliefs, estimates, forecasts, projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as “aim”; “ambition”; ”anticipate”; “aspire”, “aspiration”, ”believe”; “commit”; “commitment”; ”could”; “desire”; ”estimate”; ”expect”; ”goals”; ”intend”; ”may”; “milestones”; ”objectives”; ”outlook”; ”plan”; ”probably”; ”project”; ”risks”; “schedule”; ”seek”; ”should”; ”target”; “vision”; ”will”; “would” and similar terms and phrases. There are a number of factors that could affect the future operations of Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this press release including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shell’s products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks, including climate change; (h) risks associated with the identification of suitable potential acquisition properties and targets, and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative, judicial, fiscal and regulatory developments including tariffs and regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks, including the risks of expropriation and renegotiation of the terms of contracts with governmental entities, delays or advancements in the approval of projects and delays in the reimbursement for shared costs; (m) risks associated with the impact of pandemics, regional conflicts, such as the Russia-Ukraine war and the conflict in the Middle East, and a significant cyber security, data privacy or IT incident; (n) the pace of the energy transition; and (o) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Shell plc’s Form 20-F and amendment thereto for the year ended December 31, 2024 (available at www.shell.com/investors/news-and-filings/sec-filings.html and www.sec.gov). These risk factors also expressly qualify all forward-looking statements contained in this press release and should be considered by the reader.  Each forward-looking statement speaks only as of the date of this press release, July 31, 2025. Neither Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this press release.

Shell’s net carbon intensity

Also, in this press release we may refer to Shell’s “net carbon intensity” (NCI), which includes Shell’s carbon emissions from the production of our energy products, our suppliers’ carbon emissions in supplying energy for that production and our customers’ carbon emissions associated with their use of the energy products we sell. Shell’s NCI also includes the emissions associated with the production and use of energy products produced by others which Shell purchases for resale. Shell only controls its own emissions. The use of the terms Shell’s “net carbon intensity” or NCI is for convenience only and not intended to suggest these emissions are those of Shell plc or its subsidiaries.

Shell’s net-zero emissions target

Shell’s operating plan and outlook are forecasted for a three-year period and ten-year period, respectively, and are updated every year. They reflect the current economic environment and what we can reasonably expect to see over the next three and ten years. Accordingly, the outlook reflects our Scope 1, Scope 2 and NCI targets over the next ten years. However, Shell’s operating plan and outlook cannot reflect our 2050 net-zero emissions target, as this target is outside our planning period. Such future operating plans and outlooks could include changes to our portfolio, efficiency improvements and the use of carbon capture and storage and carbon credits. In the future, as society moves towards net-zero emissions, we expect Shell’s operating plans and outlooks to reflect this movement. However, if society is not net zero in 2050, as of today, there would be significant risk that Shell may not meet this target.

Forward-Looking non-GAAP measures

This press release may contain certain forward-looking non-GAAP measures such as divestments. We are unable to provide a reconciliation of these forward-looking non-GAAP measures to the most comparable GAAP financial measures because certain information needed to reconcile those non-GAAP measures to the most comparable GAAP financial measures is dependent on future events some of which are outside the control of Shell, such as oil and gas prices, interest rates and exchange rates. Moreover, estimating such GAAP measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-GAAP measures in respect of future periods which cannot be reconciled to the most comparable GAAP financial measure are calculated in a manner which is consistent with the accounting policies applied in Shell plc’s consolidated financial statements.

The contents of websites referred to in this press release do not form part of this press release.

We may have used certain terms, such as resources, in this press release that the United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC.  Investors are urged to consider closely the disclosure in our Form 20-F, and any amendment thereto, File No 1-32575, available on the SEC website www.sec.gov.

 

Shell completes sale of interest in Colonial Enterprises Inc. to Brookfield subsidiary

HOUSTON, Aug. 1, 2025 /PRNewswire/ — Shell Midstream Operating LLC (SMUS), a subsidiary of Shell plc (“Shell”), has completed the previously announced sale of its 16.125% interest in Colonial Enterprises, Inc. (“Colonial”) to Colossus AcquireCo LLC, a wholly owned subsidiary of Brookfield Infrastructure Partners L.P. and its institutional partners (collectively, “Brookfield”).

The divestment reflects Shell’s focus on performance, discipline and simplification and enables the company to concentrate on areas where it has scale and competitive advantage.

Notes to editors 

  • Together with Shell, the co-owners of Colonial Enterprises, Inc., have sold 100% of their Colonial shares to Brookfield. Colonial was previously divided among five partners: Shell Midstream Operating LLC (16.125%), Koch Capital Investments Company, LLC (28.088%); KKR-Keats Pipeline Investors, L.P. (23.443%); La Caisse (16.549%); and IFM Investors (IFM) (15.795%).
  • The sale values Shell’s share of Colonial at $1.45 billion, inclusive of approximately $500 million in non-recourse debt and excluding customary closing adjustments.
  • Colonial operates as an independent company and fully owns Colonial Pipeline Company (CPC), a non-operated venture, as well as Colonial Marketing Company. CPC provides oil products transportation services from the US Gulf Coast to the US Atlantic Seaboard.
  • Shell Midstream Operating LLC is an indirect, wholly owned subsidiary of Shell Pipeline Company LP, and the largest pipeline operator in the Gulf of America. It transports 1.5 billion barrels of crude oil, refined products, chemicals and NGLs annually through its vast network of pipelines and tank farms across 12 states and the Gulf of America.
  • The U.S. is a key market for Shell, where it has interests in 50 states and employs more than 11,000 people who work to provide a secure supply of energy today, while tackling the energy challenges of the future. Shell’s U.S. portfolio of operated companies and interests consists of oil, natural gas, petrochemicals, lubricants and refined fuel products along with renewables such as wind, solar, and mobility segments like electric vehicle charging.

Cautionary Note

The companies in which Shell plc directly and indirectly owns investments are separate legal entities. In this press release, “Shell”, “Shell Group” and “Group” are sometimes used for convenience to reference Shell plc and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Shell plc and its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. ”Subsidiaries”, “Shell subsidiaries” and “Shell companies” as used in this press release refer to entities over which Shell plc either directly or indirectly has control. The terms “joint venture”, “joint operations”, “joint arrangements”, and “associates” may also be used to refer to a commercial arrangement in which Shell has a direct or indirect ownership interest with one or more parties.  The term “Shell interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.

Forward-Looking statements

This press release contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition, results of operations and businesses of Shell. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Shell to market risks and statements expressing management’s expectations, beliefs, estimates, forecasts, projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as “aim”; “ambition”; ”anticipate”; “aspire”, “aspiration”, ”believe”; “commit”; “commitment”; ”could”; “desire”; ”estimate”; ”expect”; ”goals”; ”intend”; ”may”; “milestones”; ”objectives”; ”outlook”; ”plan”; ”probably”; ”project”; ”risks”; “schedule”; ”seek”; ”should”; ”target”; “vision”; ”will”; “would” and similar terms and phrases. There are a number of factors that could affect the future operations of Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this press release including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shell’s products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks, including climate change; (h) risks associated with the identification of suitable potential acquisition properties and targets, and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative, judicial, fiscal and regulatory developments including tariffs and regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks, including the risks of expropriation and renegotiation of the terms of contracts with governmental entities, delays or advancements in the approval of projects and delays in the reimbursement for shared costs; (m) risks associated with the impact of pandemics, regional conflicts, such as the Russia-Ukraine war and the conflict in the Middle East, and a significant cyber security, data privacy or IT incident; (n) the pace of the energy transition; and (o) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Shell plc’s Form 20-F and amendment thereto for the year ended December 31, 2024 (available at www.shell.com/investors/news-and-filings/sec-filings.html and www.sec.gov). These risk factors also expressly qualify all forward-looking statements contained in this press release and should be considered by the reader.  Each forward-looking statement speaks only as of the date of this press release, July 31, 2025. Neither Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this press release.

Shell’s net carbon intensity

Also, in this press release we may refer to Shell’s “net carbon intensity” (NCI), which includes Shell’s carbon emissions from the production of our energy products, our suppliers’ carbon emissions in supplying energy for that production and our customers’ carbon emissions associated with their use of the energy products we sell. Shell’s NCI also includes the emissions associated with the production and use of energy products produced by others which Shell purchases for resale. Shell only controls its own emissions. The use of the terms Shell’s “net carbon intensity” or NCI is for convenience only and not intended to suggest these emissions are those of Shell plc or its subsidiaries.

Shell’s net-zero emissions target

Shell’s operating plan and outlook are forecasted for a three-year period and ten-year period, respectively, and are updated every year. They reflect the current economic environment and what we can reasonably expect to see over the next three and ten years. Accordingly, the outlook reflects our Scope 1, Scope 2 and NCI targets over the next ten years. However, Shell’s operating plan and outlook cannot reflect our 2050 net-zero emissions target, as this target is outside our planning period. Such future operating plans and outlooks could include changes to our portfolio, efficiency improvements and the use of carbon capture and storage and carbon credits. In the future, as society moves towards net-zero emissions, we expect Shell’s operating plans and outlooks to reflect this movement. However, if society is not net zero in 2050, as of today, there would be significant risk that Shell may not meet this target.

Forward-Looking non-GAAP measures

This press release may contain certain forward-looking non-GAAP measures such as divestments. We are unable to provide a reconciliation of these forward-looking non-GAAP measures to the most comparable GAAP financial measures because certain information needed to reconcile those non-GAAP measures to the most comparable GAAP financial measures is dependent on future events some of which are outside the control of Shell, such as oil and gas prices, interest rates and exchange rates. Moreover, estimating such GAAP measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-GAAP measures in respect of future periods which cannot be reconciled to the most comparable GAAP financial measure are calculated in a manner which is consistent with the accounting policies applied in Shell plc’s consolidated financial statements.

The contents of websites referred to in this press release do not form part of this press release.

We may have used certain terms, such as resources, in this press release that the United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC.  Investors are urged to consider closely the disclosure in our Form 20-F, and any amendment thereto, File No 1-32575, available on the SEC website www.sec.gov.

 

Della Day 2025: Innovation Meets Comfort with the Launch of New Mini Split Systems

LOS ANGELES, Aug. 1, 2025 /PRNewswire/ — Della Day is the annual tradition of unveiling innovation and comfort. With so many innovations on the horizon, home comfort will be better than ever.

Della Day 2025: Home, just the way you like it.
Della Day 2025: Home, just the way you like it.

“At Della, we don’t believe in just keeping you cool, we believe in making every room feel just right. That’s what real innovation looks like,” Bob, founder of Della.

This Della Day, on August 1st, we are introducing our most advanced mini split AC systems yet, along with a refreshed version of our best-selling tower fan. Smarter living starts here.

From bold product upgrades to smarter climate control, Della Day 2025 is all about empowering homeowners with innovative solutions that deliver comfort without compromise.

Modern homes demand more than just cooling. Our latest ductless systems offer zoned climate control, year-round performance, and energy efficiency without the need for ductwork, delivering comfort that adapts to homeowners’ lifestyles.

Smarter living starts here.

Product Highlights

R-454B Multi-Zone Mini Split 

At the forefront of our new mini split launch 2025 is the R-454B multi zone mini split, offering unmatched flexibility for large homes and unique layouts.

  •  Custom climates, five zones at a time. 

    At the forefront of our new mini split launch 2025 is the R-454B multi zone mini split, offering unmatched flexibility for large homes and unique layouts. Each system supports up to five zones, letting you create custom climates in bedrooms, kitchens, offices, and more.

  • Tailored zones. Flexible setup.

    Users can customize the cooling and heating power for each room by selecting the right size for their space, from a cozy 400 sq. ft. bedroom to a large 1,500 sq. ft. living area. This flexibility helps maximize comfort and efficiency throughout the home.

    Installation is easier than ever with pre-charged 25-foot copper linesets per zone (up to 125 feet total), making it a great option for DIYers and contractors alike.

  • Greener performance, built to last.

    This is also our first R-454B refrigerant mini split, using an eco-friendly refrigerant with a significantly lower Global Warming Potential (GWP). It aligns with evolving EPA standards and is designed to future-proof your investment.

R32 Dual-Zone System

Modern homes demand more than just cooling. Our latest ductless systems offer the perfect combination of zoned climate control, year-round heating and cooling, and energy efficiency.

Need something more compact? Our R32 dual-zone mini split AC is a high-performance option for smaller homes or tighter budgets. It delivers the same powerful year-round climate control with a smaller footprint.  They deliver the best value for smaller spaces while providing comfort tailored to homeowners’ lifestyles.

It’s a smart, budget-friendly entry point into ductless AC for home comfort that doesn’t sacrifice technology or quality.

Della Tower Fan

Also returning just in time for summer is our signature Della tower fan, now with an even sleeker design. With upgraded airflow, remote and LED controls, and ultra-quiet operation, it’s a stylish addition to any room. Whether used on its own or alongside a smart mini split system, the Della tower fan enhances comfort across all seasons.

Smarter, Simpler Comfort

All Della systems, including our mini splits and fans, are powered by the DELLA+ app, allowing users to control settings, temperatures, and scheduling directly from their smart phones. It’s part of our promise to deliver smarter comfort with less hassle.

We also stand behind every system with the Della lifetime warranty (available for pro-installed units) and Della 24/7 live chat support, ensuring real-time help whenever you need it.

From built-in diagnostics to future tech like video-assisted troubleshooting, Della is redefining what it means to own a smart mini split system in 2025.

Comfort Designed for Real Life

At Della, innovation starts with people. Whether it’s a sleek ductless air conditioner, a modern tower fan, or a fully customizable multi zone mini split, we design each product with real homes and real comfort, always in mind.

Breathe life into your home with smarter, more sustainable solutions. Discover the future of climate control at www.dellahome.com.

 

Canada’s Largest Bitcoin ATM Operator Now Offers Solana ($SOL)

TORONTO, Aug. 1, 2025 /PRNewswire/ — Localcoin, a leader in the cryptocurrency ATM industry, announces the addition of Solana ($SOL) to its extensive network of Bitcoin ATMs across Canada, Australia, New Zealand, and Hong Kong. As the largest provider in these regions to offer $SOL purchases with cash, Localcoin reaffirms its mission to expand access to innovative cryptocurrencies and empower users to diversify their digital asset portfolios with ease.

Buy Solana at 1,000+ Localcoin ATM
Buy Solana at 1,000+ Localcoin ATM

Solana Now Available at Localcoin ATMs
Users can now buy Solana ($SOL) with cash at Localcoin ATMs. Renowned for its high-speed, low-cost blockchain and thriving ecosystem of decentralized applications (dApps), Solana is a preferred choice for crypto enthusiasts and investors worldwide. This addition aligns with Localcoin’s commitment to making cutting-edge cryptocurrencies accessible, secure, and simple for all users.

“At Localcoin, we’re not just leading the way—we’re shaping the future of crypto accessibility. Being the largest operator to offer Solana ($SOL) purchases with cash is a milestone, but it’s just the beginning. Our team is focused on expanding our ATM network, introducing more innovative digital assets, and building a platform that makes crypto simple, secure, and available to everyone, “ said Tristan Fong, CEO of Localcoin.

How to Buy Solana at Localcoin ATMs

Step 1 – Obtain a Solana Wallet
Before visiting an ATM, ensure you have a compatible Solana wallet and its QR code ready.

Step 2 – Locate a Nearby ATM
Use Localcoin’s ATM locator to find the closest machine to your location.

Step 3 – Initiate Your Transaction
 At the Localcoin ATM:

  • Select Solana ($SOL) as your cryptocurrency.
  • Scan your wallet’s QR code using the ATM scann

Step 4 – Finalize Your Purchase
Insert cash and review the displayed amount. A service fee will apply based on the current $SOL market rate. Use code SOL35 for 35% off transaction fees when purchasing $SOL.

Step 5 – Receive Your Solana
Once confirmed, $SOL will be sent directly to your wallet address.

Why Solana?

Solana is capable of finalizing transactions in under half a second and can process up to 65,000 transactions per second. Its speed and scalability make it a favorite among developers and investors.

As of July 22, 2025, Solana’s market capitalization exceeds $108 billion, ranking it among the world’s leading cryptocurrencies.

About Solana ($SOL)

Solana is the native cryptocurrency of the Solana blockchain, a high-performance Layer 1 platform launched in 2020 by Solana Labs, founded by Anatoly Yakovenko and Raj Gokal. Known for its hybrid Proof-of-Stake (PoS) and Proof-of-History (PoH) consensus, Solana delivers fast, secure, and decentralized transactions at minimal cost. It powers a growing ecosystem of decentralized finance (DeFi), non-fungible tokens (NFTs), and gaming applications.

About Localcoin

Localcoin empowers individuals worldwide to easily convert cash into crypto. With thousands of ATMs across Canada, Australia, New Zealand, and Hong Kong, Localcoin offers a seamless gateway into the digital financial ecosystem.
From payments and remittances to online purchases and investments, Localcoin ATMs provide secure, convenient access to the crypto economy.

 

ASSEMBLY APPOINTS ALAP GHOSH AS FIRST CEO OF INDIA

Former Google India executive to lead unified national operations across Mumbai and Bangalore.

MUMBAI, India, Aug. 1, 2025 /PRNewswire/ — Assembly, a global omnichannel media agency within the Stagwell network, today announced the appointment of Alap Ghosh as its first-ever CEO for India. Based in Mumbai, Ghosh will officially step into the role on August 1, 2025, and report to Matt Adams, Global COO of Assembly. Ghosh brings deep expertise across the digital ecosystem, having worked with advertising technology, marketing technology, and programmatic platforms throughout his career.

Alap Ghosh Headshot
Alap Ghosh Headshot

A seasoned leader with over 25 years of experience in building, managing, and marketing digital-first businesses, Ghosh joins Assembly from Google India, where he served as Head of Data and Technology Partnerships. In this role, he was responsible for marketing technology and digital innovation mandates for Google’s enterprise partners and clients. He previously held leadership roles at Jellyfish and founded his own data consultancy, and has extensive experience across supply, demand, innovation, and revenue functions. With a proven track record in building teams, scaling operations, and driving digital advancement, Ghosh brings the strategic vision and operational expertise needed to lead Assembly’s next phase of growth in India.

In his new role, Ghosh will oversee the integration of Assembly’s media business across Mumbai and Bangalore to establish a unified offering spanning media, creative, technology, and commerce. His leadership will focus on accelerating growth and building more connected omnichannel experiences that make brands perform across the region.

“Alap’s appointment marks an exciting new chapter for Assembly in India,” said Rick Acampora, Assembly Global CEO. “India is an important growth market for Assembly and for many of our global clients, and we’re committed to realizing its full potential. Alap brings the right mix of cross-sector experience and proven leadership to help us build something genuinely differentiated in this region.”

“I’m excited to join Assembly at such a pivotal moment for Assembly and for India,” said Ghosh. “By bringing our teams together, with one vision and voice, we can create something bold, unified, and fit for purpose for what’s next for India. India is moving fast—creatively, culturally, and digitally—and we have a real opportunity to build an offering that delivers for today’s clients and sets a new benchmark for what’s possible in this market’s future.”

ABOUT ASSEMBLY
Assembly is a global omnichannel agency built for brands that want a more modern approach to building brands that perform. Backed by the Stagwell network, we are a literal assembly of data, talent, and technology built to unlock smarter, faster, and better-performing outcomes from the bottom up, not the top down. Curious, collaborative, and driven by change, we are an agency of builders who believe the better the experience, the better the brand performance. We don’t see brand and performance as an either/or. For us, it’s always both. The + symbol in our logo, known as the ORAD, represents this mindset. It’s a mark of how we think, how we build, and how we deliver results across the full funnel. Assembly’s foundation is built on three core elements: our purpose-built STAGE Experience Engine, the strategic product it powers – Brand Performance Planning (BPP) – and an organizational design built for speed, depth, and the demands of modern marketing. Together, they enable us to build better brand experiences that reimagine how brands connect, engage, and grow across data, tech, media, creative, and commerce.  With over 3,000 experts in 44 offices worldwide, Assembly delivers full-funnel solutions that help the world’s most ambitious brands perform. Learn more at assemblyglobal.com.

MEDIA RELATIONS CONTACT:  
Jess Santini
jess.santini@assemblyglobal.com  

 

OSR Holdings Provides Transparency Update on Equity Financing Instruments

BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ — OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovation approaches to health and wellness to support global health outcomes, today provided a transparency update regarding its Equity Line of Credit (ELOC) agreement with White Lion GBM Innovation Fund and related convertible instruments.

Highlights:

  • Total shares issued to date under structured financing: 2,308,382
    • Commitment Shares: 519,481
    • Convertible Notes: 745,193
    • Warrant Exercises: 276,208
  • Under the ELOC agreement:
    • Registered Share Capacity: 9,500,000
    • Shares Issued Since June 17, 2025 (Effecitve Date of S-1/A): 767,500
    • Utilization: Less than 10% of total registered shares

“While structured financing mechanisms like ELOCs, warrants, and convertible notes inherently carry dilution risk, it’s important to emphasize that any future issuance under our ELOC is not purely dilutive,” said Peter Hwang, CEO of OSRH. “Proceeds from these financings are being invested directly into our business, enabling accelerated development across our drug R&D pipeline, medical device initiatives, and digital asset ecosystems.”

Dilution to date has been limited and tightly managed, with less than 10% of registered shares issued under the ELOC. OSRH is committed to protecting shareholder value by aligning all financing activity with near-term growth objectives.

OSRH remains confident that its current share price does not reflect the company’s intrinsic value, which includes:

  • A “Plug-and-Play” bacterial vector platform for cancer immunotherapy
  • A Disease-Modifying Osteoarthritis Drug (DMOAD) candidate
  • A strategic move toward acquiring noninvasive glucose monitoring technology through a signed term sheet with Woori IO

Woori IO Transaction Update:

“While not disclosed in our initial announcement, Woori IO’s clinical trial in Korea is being conducted in partnership with one of the world’s largest technology companies in the mobile and wearable devices space,” said Mr. Hwang. “We intend to provide full transparency on this relationship following the signing of the Stock Purchase Agreement, which we expect to complete in good faith by the end of October.”

About OSR Holdings, Inc.

OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno‑oncology, regenerative biologics, and medical device distribution. OSRH’s vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting‑edge research and development. For more information, visit www.OSR‑Holdings.com.